Based on previous evidence, such as that from the RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) study and the IDNT (Irbesartan Diabetic Nephropathy Trial)1, renin‐angiotensin‐aldosterone (RAAS) inhibitors have been recognized as a specific drug for DKD. The gene discussed is REN; the disease is diabetic kidney disease.